Navigation Links
Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical,Potential

f a week. We believe a more efficacious, easier-to-use typhoid fever vaccine could greatly expand the current markets for both travelers in developed countries and mass immunization programs in developing countries.”

The Phase 1/2 study was an in-patient dose-escalating clinical trial aimed at determining the safety and immunogenicity of the single-dose, oral Ty800 vaccine. The trial evaluated three escalating dose levels of the vaccine in 47 healthy adult volunteers and followed each volunteer for six months post-vaccination. The clinical trial was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), and was conducted at the Cincinnati Children’s Hospital Medical Center. This clinical trial has been funded in whole or in part with Federal funds from the NIAID of the NIH, Department of Health and Human Services, under contract No. NO AI 25459.

About the Ty800 Vaccine
AVANT has designed the Ty800 vaccine to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S. typhi. The clinical trial was designed to show whether Ty800 would be well tolerated in humans and rapidly elicit strong immune responses.

The Study
A total of 47 healthy volunteers participated in the Ty800 study. Thirty-three subjects were randomly sorted into three different dose groups having mean doses administered of 8x107, 6x108 and 1x1010 colony-forming units (CFUs) and 14 received a placebo consisting of buffer only. The dose of 6x108 CFU in this study appeared to be immunogenic with similar reactogenicity as placebo. In addition, over 90% of vaccinees showed positive immune responses for both systemic (IgG) and mucosal (IgA) antibodies to typhoid based on an ELISPOT assay. Results of the study are being p
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Avants Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential
2. SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193
3. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
7. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
8. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
9. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
10. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
11. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
Post Your Comments:
(Date:3/26/2015)... -- "Whether it,s our family, our friends, all of ... a single sentence, Dr. Anthony Coyle , senior ... Centers for Therapeutic Innovation (CTI), sums up what ... biopharmaceutical companies. CTI,s unique model allows ... and the National Institutes of Health (NIH) to bridge ...
(Date:3/26/2015)... YORK , March 26, 2015 ... the average American consumer. However, a new survey ... various ailments from the common cold to diabetes, ... The research, conducted by the Private Label ... on over-the-counter healthcare products, including those essential for ...
(Date:3/26/2015)... Research and Markets ( ... "Global Smart Wearable Healthcare Devices and Services ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The analysts forecast ... market to grow at a CAGR of 30.42% ... covers the present scenario and the growth prospects ...
Breaking Medicine Technology:Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Consumers can keep over-the-counter medicine affordable by using store brands 2Global Smart Wearable Healthcare Devices and Services Market 2015-2019 WITH Apple, At&T, Ee, Google, Samsung, Sprint, Telefonica & T-Mobile Dominating 2
... WOODCLIFF LAKE, N.J., Nov. 3, 2010 Par Pharmaceutical Companies, ... the third quarter ended September 30, 2010. For ... total revenues of $234.4 million and income from continuing operations ... included a $2.0 milestone payment to Tris Pharma, Inc., a ...
... 2010 Regado Biosciences, Inc., a privately held company ... agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior ... at the American College of Chest Physicians (ACCP) Coagulation ... Vancouver, BC, Canada.  The abstract is titled "Sustained Inhibition ...
Cached Medicine Technology:Par Pharmaceutical Companies Reports Third Quarter 2010 Results 2Par Pharmaceutical Companies Reports Third Quarter 2010 Results 3Par Pharmaceutical Companies Reports Third Quarter 2010 Results 4Par Pharmaceutical Companies Reports Third Quarter 2010 Results 5Par Pharmaceutical Companies Reports Third Quarter 2010 Results 6Par Pharmaceutical Companies Reports Third Quarter 2010 Results 7Par Pharmaceutical Companies Reports Third Quarter 2010 Results 8Par Pharmaceutical Companies Reports Third Quarter 2010 Results 9Par Pharmaceutical Companies Reports Third Quarter 2010 Results 10Par Pharmaceutical Companies Reports Third Quarter 2010 Results 11Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 2Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010 3
(Date:3/27/2015)... March 27, 2015 “ VXi BlueParott ... its monthly Tech Report, which features the latest and ... technology expert and special reporter for NewsWatch, conducted the ... advanced noise-cancelling headset, eliminating 90% of ambient noise. , ... texts and emails are important to any professional, voice ...
(Date:3/27/2015)... In light of two lawsuits that ... District Court, District of Massachusetts; and case number 2:15-cv-00709PD, ... Pennsylvania), the San Diego personal injury lawyers of The ... that they are available to investigate potential birth ... prescribed Zofran while pregnant and who gave birth to ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Elfster.com, the ... addition of its bucket list generator capabilities to its ... course, refers to a list that one creates of ... the 2007 movie of the same name. Nowadays ... way to memorialize their summer achievements. , "We are ...
(Date:3/26/2015)... San Diego (PRWEB) March 26, 2015 ... to advance health and wellness for the poor and ... the application period for its annual $1 million award, ... is excited to announce the 2015 round of our ... "We've seen and supported some incredibly creative and ambitious ...
(Date:3/26/2015)... 26, 2015 The American College of Traditional ... the topics of the DAOM Program as well as Marketing ... Webinar will be hosted by Dr. Carla Wilson, who will ... steps on how to prepare for the spring quarter. The ... March 27, April 1 and April 3. Attendees can log ...
Breaking Medicine News(10 mins):Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2Health News:The Law Office of Melinda J. Helbock, A.P.C. Announces That It Is Now Accepting Case Reviews for Potential Zofran Birth Defect Lawsuits 2Health News:Plans for Bucket List Generator - Just In Time for Summer - Announced by Elfster 2Health News:Applications Open for $1M Innovation Initiative Award from Alliance Healthcare Foundation 2Health News:ACTCM Announces Upcoming Webinars 2
... Cellmark Inc.,(Nasdaq: ORCH ), a leading worldwide provider ... for the fourth quarter and,full year of 2007., ... the fourth,quarter of 2007 compared to $14.9 million for ... 2007, revenues were $60.3 million compared to $56.9,million for ...
... The International,Society for CNS Clinical Trials ... in Washington, DC, February 25-27. This organization,involves ... of the pharmaceutical industry, and governmental,drug-regulatory bodies ... safety,of drugs used to treat psychiatric and ...
... Health Net,s Roger and Erika Greaves; CNN,s ... of Humanity Award, SHERMAN OAKS, Calif., March 5 ... prevent pediatric,burns and to heal severely burned children, celebrated its ... on Feb. 21. The event,was attended by more than 700 ...
... N.J., March 5 Besler,& Company, Inc., a ... agreed to pay the United States $2.875 million, ... federal Medicare program, the,Justice Department announced today., ... company counseled hospital clients to improperly,increase charges to ...
... ten elderly adults on Medicare reports drinking more alcohol ... Brandeis University. , Even though alcohol problems are ... older adults are consuming alcohol in amounts that exceed ... at Brandeis Universitys Heller School for Social Policy and ...
... Answer That Question, BREA, Calif., March 5 ... site in the United States, now,helps pet owners ... are with a quick and humorous online Canine ... gauges pet owner,responses to determine their dog,s brain ...
Cached Medicine News:Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 7Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 8Health News:Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results 9Health News:FDA Warning of Suicidal Risk Associated with Antidepressants in Juveniles and Young Adults Reviewed at Recent ISCTM Meeting 2Health News:Children's Burn Foundation's Benefit Raises More Than $875,000 for Burn Survivors and Prevention 2Health News:Children's Burn Foundation's Benefit Raises More Than $875,000 for Burn Survivors and Prevention 3Health News:New Jersey Healthcare Consulting Firm to Pay U.S. $2.875 Million to Resolve Allegations of Medicare Fraud 2Health News:New study sheds light on excessive drinking among the elderly 2Health News:Is Your Dog a Canine-stein or a Bonehead? 2Health News:Is Your Dog a Canine-stein or a Bonehead? 3
... Cycler is Thermo Electron's most advanced personal ... easy to use sophisticated onboard software and ... Designed to offer performance, accuracy and simplicity ... number of customer driven features built up ...
... Design With Exceptional Performance The ... interface might be the first ... MyCycler is designed for performance. ... a premium, its small footprint ...
96 well thermocycler with unique High Temperature Range (HTR) Peltier technology for fastest available heating and cooling rates up to 4C/sec with High Pressure Lid for automated sealing of PCR plate...
... Faster speeds, highest precision, more user-friendliness ... concept: this is the definition of the ... years nucleic acid research has been developing ... required of PCR Systems. To keep ...
Medicine Products: